Results 101 to 110 of about 5,889,184 (390)

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.

New England Journal of Medicine, 2019
BACKGROUND Apalutamide is an inhibitor of the ligand-binding domain of the androgen receptor. Whether the addition of apalutamide to androgen-deprivation therapy (ADT) would prolong radiographic progression-free survival and overall survival as compared ...
K. Chi, N. Agarwal, A. Bjartell, B. Chung, A. J. Pereira de Santana Gomes, R. Given, Á. Juárez Soto, A. Merseburger, M. Özgüroğlu, H. Uemura, D. Ye, K. Deprince, V. Naini, Jinhui Li, Shinta Cheng, Margaret K Yu, Ke Zhang, J. Larsen, S. McCarthy, S. Chowdhury   +19 more
semanticscholar   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

What is the risk of prostate cancer mortality following negative systematic TRUS-guided biopsies? A systematic review

BMJ Open, 2020
Objective To investigate the risk of prostate cancer-specific mortality (PCSM) following initial negative systematic transrectal ultrasound-guided (TRUS) prostate biopsies.Design Systematic review.Data sources PubMed and Embase were searched using a ...
Klaus Brasso, Martin Andreas Roder, Sandra Miriam Kawa, Signe Benzon Larsen, John Thomas Helgstrand, Peter Iversen   +5 more
doaj   +1 more source

Genomic correlates of clinical outcome in advanced prostate cancer

Proceedings of the National Academy of Sciences of the United States of America, 2019
Significance The genomic landscape of metastatic castration-resistant prostate cancer (mCRPC) has been well-defined, but the association of genomic findings with patient clinical outcomes and with other characteristics including histology and ...
W. Abida, J. Cyrta, G. Heller, D. Prandi, J. Armenia, Ilsa M Coleman, M. Cieslik, M. Benelli, D. Robinson, E. V. Van Allen, A. Sboner, T. Fedrizzi, J. Mosquera, B. Robinson, N. De Sarkar, L. Kunju, S. Tomlins, Yi Mi Wu, Daniel Nava Rodrigues, M. Loda, A. Gopalan, V. Reuter, C. Pritchard, J. Mateo, D. Bianchini, S. Miranda, S. Carreira, P. Rescigno, J. Filipenko, J. Vinson, R. Montgomery, H. Beltran, E. Heath, H. Scher, P. Kantoff, M. Taplin, N. Schultz, J. Debono, F. Demichelis, P. Nelson, M. Rubin, A. Chinnaiyan, C. Sawyers   +42 more
semanticscholar   +1 more source

Cis‐regulatory and long noncoding RNA alterations in breast cancer – current insights, biomarker utility, and the critical need for functional validation

Molecular Oncology, EarlyView.
The noncoding region of the genome plays a key role in regulating gene expression, and mutations within these regions are capable of altering it. Researchers have identified multiple functional noncoding mutations associated with increased cancer risk in the genome of breast cancer patients.
Arnau Cuy Saqués, Aracele Martinez‐Mendez, John Crown, Alex Eustace   +3 more
wiley   +1 more source

Role of Epigenetic Modification and Immunomodulation in a Murine Prostate Cancer Model [PDF]

, 2016
INTRODUCTION. Decreased expression of highly immunogenic cancer-testis antigens (CTA) might help tumor to achieve low immunogenicity, escape immune surveillance and grow unimpeded. Our aim was to evaluate CTA expression in tumor and normal tissues and to
Goliadze, Ekaterine, Guruli, Georgi, Manjili, Masoud H., Petrossian, Albert A., Robinson, Samuel P., Sulek, Jay E., Toor, Amir, Zhou, Shaoqing   +7 more
core   +2 more sources

The Role of Curcumin in Prostate Cancer Cells and Derived Spheroids [PDF]

, 2022
Mariarosaria Boccellino, Pasqualina Ambrosio, Andrea Ballini, Danila De Vito, Salvatore Scacco, Stefania Cantore, Antonia Feola, Marzia Di Donato, Lucio Quagliuolo, Antonella Sciarra, Giovanni Galasso, Felice Crocetto, Ciro Imbimbo, Silvia Boffo, Erika Di Zazzo, Marina Di Domenico   +15 more
openalex   +1 more source

Enzalutamide in metastatic prostate cancer before chemotherapy.

New England Journal of Medicine, 2014
BACKGROUND Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer in whom the disease has progressed after chemotherapy.
T. Beer, A. Armstrong, D. Rathkopf, Y. Loriot, Cora N. Sternberg, C. Higano, P. Iversen, S. Bhattacharya, J. Carles, S. Chowdhury, Ian D. Davis, J. D. de Bono, Christopher P Evans, K. Fizazi, Anthony M. Joshua, Choung-Soo Kim, G. Kimura, P. Mainwaring, H. Mansbach, K. Miller, S. Noonberg, F. Perabo, D. Phung, F. Saad, H. Scher, M. Taplin, P. Venner, B. Tombal   +27 more
semanticscholar   +1 more source

European Code Against Cancer, 5th edition – hormone replacement therapy, other common medical therapies and cancer

Molecular Oncology, EarlyView.
The 5th edition of the European Code Against Cancer (ECAC5) contains 14 recommendations on cancer prevention. Here, we update the cancer prevention recommendations regarding the use of hormone replacement therapy (HRT), which is positioned as recommendation number 13 of the ECAC5.
Mangesh A. Thorat, Marc Arbyn, David Baldwin, Xavier Castells, Solveig Hofvind, Urska Ivanus, Carlo Senore, Esther Toes‐Zoutendijk, Carlijn van der Aalst, Carlos Canelo‐Aybar, Fiorella Karina Fernández‐Sáenz, Ariadna Feliu, Hajo Zeeb, Andre L. Carvalho, Erica D'Souza, David Ritchie, Carolina Espina, Iris Lansdorp‐Vogelaar, Andrea DeCensi   +18 more
wiley   +1 more source

Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications. [PDF]

, 2019
The increasing number of patients with sequenced prostate cancer genomes enables us to study not only individual oncogenic mutations, but also capture the global burden of genomic alterations.
Bose, Rohit, Ryan, Matthew J
core   +1 more source